生物醫藥技術全國重點實驗室
（香港大學）
State Key Laboratory of Pharmaceutical Biotechnology
（The University of Hong Kong)
Field of Research
Study on the functions and mechanisms of novel hormones in obesity-related metabolic diseases.
Biography
Dr. Yang Ranyao received his PhD from the University of Hong Kong in 2020 and completed his postdoctoral training in 2022. His current research primarily focuses on the discovery of novel hormones and their roles in metabolism. Utilizing gene editing techniques such as AAV and CRISPR/Cas9, Dr. Yang explores the gain- and loss-of-function effects of these hormones. He has identified several hormones with potential diagnostic and therapeutic applications in obesity-related diseases, including diabetes, non-alcoholic steatohepatitis. Notably, Dr. Yang has made significant advances in understanding pancreatic β-cell dysfunction and developing potential regenerative therapies for diabetes. His work aims to identify novel molecular targets that can promote β-cell regeneration and enhance glycemic control, addressing a critical unmet need in diabetes treatment.
Publications
-
Zhang L, Li H, Sun F, Wu Q, Jin L, Xu A, Chen J, Yang R*. Identification of novel markers for neuroblastoma immunoclustering using machine learning. Front Immunol. 2024 Nov 4;15:1446273.
-
Yang R, Xu A, Kharitonenkov A. Another kid on the block: long-acting FGF21 analog to treat dyslipidemia and fatty liver. J Clin Endocrinol Metab. 2022 Jan 1;107(1):e417-e419.
-
Yang R, Hu Y, Lee CH, Liu Y, Diaz-Canestro C, Fong CHY, Lin H, Cheng KKY, Pravelil AP, Song E, Lam KS and Xu A. PM20D1 is a Circulating Biomarker Closely Associated with Obesity, Insulin resistance and Metabolic Syndrome. Eur J Endocrinol. 2021 Dec 10;186(2):151-161.
-
Yang R, Jiang X, He X, Liang D, Sun S, Zhou G. Ginsenoside Rb1 Improves Cognitive Impairment Induced by Insulin Resistance through Cdk5/p35-NMDAR-IDE Pathway. Biomed Res Int. 2020 May 20; 2020: 3905719.
-
Yang RY, Zhao G, Wang DM, Pang XC, Wang SB, Fang JS, Li C, Liu AL, Wu S, Du GH. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice. Pharmacol Biochem Behav. 2015 Dec;139(Pt A):15-26.
-
Fang J#, Yang R#, Gao L, Yang S, Pang X, Li C, He Y, Liu AL, Du GH. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery. Mol Divers. 2015 Feb;19(1):149-62. (#co-first author)
-
National Natural Science Foundation of China: The role and mechanism of PM20D1 in regulating insulin resistance induced by high fat diet based on mitochondrial function (No.: 81800754). (PI)
-
Natural Science Foundation of Shandong Province: Ginsenoside Rb1 Reverse Cognitive Impairment Induced by Insulin Resistance (No.: ZR2016HP16). (PI)
Patent
PCT International Application: STANNIOCALCIN 2 (STC2) AND DERIVATIVES AS ANTI-DIABETIC AGENTS (No.: PCT/CN2025/106844)